Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy
NIHR HSRIC
Record ID 32016000636
English
Authors' objectives:
Breast cancer is the most common cancer in the UK. There are many types of breast cancer. Pertuzumab is a new treatment which is currently in development for one type of breast cancer called HER2-positive. It will be used to treat early stage cancer, and will be given after breast surgery. Pertuzumab is injected into the bloodstream and is given in addition to the current standard treatments of trastuzumab and chemotherapy.
Pertuzumab is currently being studied to see whether it improves survival and whether it is safe to use in people with breast cancer. If pertuzumab is licenced for use in the UK, it will provide a new treatment option for patients with one type of early breast cancer.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/pertuzumab-perjeta-with-chemotherapy-and-trastuzumab-for-her2-positive-early-breast-cancer-adjuvant-therapy/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Adjuvants, Immunologic
- Adjuvants, Pharmaceutic
- Antibodies, Monoclonal, Humanized
- Breast Neoplasms
- Trastuzumab
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.